|
|
【DPHARMA 7148 交流专区】（前名 CCMDBIO）
[复制链接]
|
|
|
发表于 6-4-2018 12:33 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 13-4-2018 06:32 PM
|
显示全部楼层
Type | Announcement | Subject | TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS)
RELATED PARTY TRANSACTIONS | Description | CCM DUOPHARMA BIOTECH BERHAD (CCMD OR COMPANY)(I) GRANT OF LICENSE FOR TRADE MARKS BY CHEMICAL COMPANY OF MALAYSIA BERHAD (CCMB);(II) PURCHASE OF TRADEMARKS FROM CCMB ; AND(III) PROVISION OF INFORMATION TECHNOLOGY (IT) SERVICES BY CCMB.(COLLECTIVELY, THE TRANSACTIONS) | The Board of Directors of CCMD (“Board”) wishes to announce that the Company had on 11 April 2018 entered into the following agreements:
(I) Trade Marks License Agreement with CCMB (“Trade Marks License Agreement”) in respect of the grant by CCMB of license and right for CCMD and its affiliates to use the trademarks associated with the “CCM leaf logo” and “CCM” (“Licensing of Trade Marks”) for a consideration of RM250,000 per annum;
(II) Sale and purchase agreement of trade marks with CCMB (“Trade Mark SPA”) for the purchase of trademarks by CCMD for a total purchase consideration of RM73.00 (“Transfer of Trademarks”); and
(III) Information Technology Services Agreement with CCMB (“IT Services Agreement”) for the IT management services, and systems, applications and products (“SAP”) services based on the rates detailed out in Section 2.3 of the attached announcement (“Provision of IT Services”).
(Collectively, the Licensing of Trademarks, the Transfer of Trademarks and the Provision of IT Services are to be referred to as the “Transactions”.)
In view of the interest of Permodalan Nasional Berhad (“PNB”) who is a common major shareholder of CCMD and CCMB, the Transactions are deemed as related party transactions pursuant to Paragraph 10.08 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.
The details of the Transactions is as per attachment.
This announcement is dated 11 April 2018. |
http://www.bursamalaysia.com/market/listed-companies/company-announcements/5755497
|
|
|
|
|
|
|
|
|
|
|
|
发表于 14-4-2018 07:47 AM
|
显示全部楼层
本帖最后由 icy97 于 16-4-2018 02:33 AM 编辑
Type | Announcement | Subject | TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS)
RELATED PARTY TRANSACTIONS | Description | CCM DUOPHARMA BIOTECH BERHAD ("CCMD" OR "THE COMPANY") PROPOSED ACQUISITION OF 806,450 COMMON SHARES IN PANGEN BIOTECH INC. ("PANGEN") ("PANGEN SHARES") REPRESENTING APPROXIMATELY 8.39% EQUITY INTEREST IN PANGEN FROM CHEMICAL COMPANY OF MALAYSIA BERHAD ("CCMB") FOR A TOTAL PURCHASE CONSIDERATION OF RM59.16 MILLION (EQUIVALENT TO KRW16.35 BILLION) TO BE SATISFIED ENTIRELY IN CASH ("PROPOSED ACQUISITION") | On behalf of the Board of Directors of CCMD, UOB Kay Hian Securities (M) Sdn Bhd wishes to announce that on 13 April 2018, the Company has entered into a conditional share sale agreement with CCMB for the acquisition of 806,450 PanGen Shares representing approximately 8.39% equity interest in PanGen for a total purchase consideration of RM59.16 million (equivalent to KRW16.35 billion) to be satisfied entirely in cash.
Further details on the Proposed Acquisition are set out in the attachment enclosed.
This Announcement is dated 13 April 2018. |
http://www.bursamalaysia.com/market/listed-companies/company-announcements/5758781
|
|
|
|
|
|
|
|
|
|
|
|
发表于 5-5-2018 05:08 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 30-5-2018 04:51 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
31 Mar 2018 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31 Mar 2018 | 31 Mar 2017 | 31 Mar 2018 | 31 Mar 2017 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 133,259 | 120,994 | 133,259 | 120,994 | | 2 | Profit/(loss) before tax | 13,255 | 11,176 | 13,255 | 11,176 | | 3 | Profit/(loss) for the period | 10,647 | 8,618 | 10,647 | 8,618 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 10,782 | 8,618 | 10,782 | 8,618 | | 5 | Basic earnings/(loss) per share (Subunit) | 3.82 | 3.43 | 3.82 | 3.43 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.7400 | 0.7200
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 11-6-2018 02:01 AM
|
显示全部楼层
Type | Announcement | Subject | NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
OTHER ISSUE OF SECURITIES | Description | CCM DUOPHARMA BIOTECH BERHAD ("CCMD" OR "THE COMPANY") (I) BONUS ISSUE; AND(II) DIVIDEND REINVESTMENT PLAN | The terms used herein, unless the context otherwise stated, bear the same meaning as those defined in the earlier announcements in relation to the Proposals.
We refer to our earlier announcements dated 27 February 2018, 30 March 2018 and 11 April 2018 in relation to the Proposals.
On behalf of the Board, UOB Kay Hian Securities (M) Sdn Bhd (“UOBKH”) wishes to announce that the issue price of the new CCMD Shares to be issued pursuant to the DRP has been fixed today (“Price Fixing Date”) at RM1.23 per new CCMD Share.
The issue price is computed based on the volume weighted average market price for the five (5) market days prior to the Price Fixing Date (up to and including 30 May 2018) of RM3.22 minus the first and final single-tier dividend per CCMD Share of 0.06 sen and thereafter adjusting for the effects of the Bonus Issue and also applying a discount of approximately 9.56%.
On behalf of the Board, UOBKH also wishes to announce that the book closure date for the first and final single-tier dividend and dividend reinvestment plan (“DRP”) shall be 18 June 2018 whilst the book closure date for the Bonus Issue shall be 19 June 2018.
Barring any unforeseen circumstances, the new CCMD Shares arising from the DRP will be listed on the Main Market of Bursa Securities on 18 July 2018.
This announcement is dated 31 May 2018. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 11-6-2018 02:23 AM
|
显示全部楼层
EX-date | 14 Jun 2018 | Entitlement date | 19 Jun 2018 | Entitlement time | 05:00 PM | Entitlement subject | Bonus Issue | Entitlement description | Bonus issue of up to 371,945,333 new ordinary shares in CCMD ("CCMD Shares") ("Bonus Shares") to be credited as fully paid-up on the basis of 4 Bonus Shares for every 3 existing CCMD Shares held by shareholders of CCMD whose names appear on the Record of Depositors as at 5.00 p.m. on 19 June 2018 ("Entitlement Date") ("Bonus Issue") | Period of interest payment | to | Financial Year End | 31 Dec 2018 | Share transfer book & register of members will be | to closed from (both dates inclusive) for the purpose of determining the entitlement | Registrar or Service Provider name, address, telephone no | Tricor Investor & Issuing House Services Sdn BhdUnit 32-01, Level 32, Tower AVertical Business Suite, Avenue 3Bangsar SouthNo. 8, Jalan Kerinchi59200 Kuala LumpurTel: 603 - 2783 9299 Fax: 603 - 2783 9222 | Payment date |
| | a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers | 19 Jun 2018 | b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit |
| | c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange. | Number of new shares/securities issued (units) (If applicable) |
| | Entitlement indicator | Ratio | Ratio | 4 : 3 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 11-6-2018 02:26 AM
|
显示全部楼层
EX-date | 13 Jun 2018 | Entitlement date | 18 Jun 2018 | Entitlement time | 05:00 PM | Entitlement subject | Final Dividend (with Dividend Re-Investment Plan) | Entitlement description | Final Single-Tier Dividend of RM0.06 per ordinary share | Period of interest payment | to | Financial Year End | 31 Dec 2017 | Share transfer book & register of members will be | to closed from (both dates inclusive) for the purpose of determining the entitlement | Registrar or Service Provider name, address, telephone no | Tricor Investor & Issuing House Services Sdn BhdUnit 32-01, Level 32, Tower AVertical Business Suite, Avenue 3Bangsar SouthNo. 8, Jalan Kerinchi59200 Kuala LumpurTel: 603 - 2783 9299 Fax: 603 - 2783 9222 | Payment date | 17 Jul 2018 | a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers | 18 Jun 2018 | b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit |
| | c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange. | Number of new shares/securities issued (units) (If applicable) |
| | Entitlement indicator | Currency | Currency | Malaysian Ringgit (MYR) | Entitlement in Currency | 0.06 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 30-6-2018 03:11 AM
|
显示全部楼层
Type | Announcement | Subject | TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS)
RELATED PARTY TRANSACTIONS | Description | CCM DUOPHARMA BIOTECH BERHAD ("CCMD" OR "THE COMPANY") PROPOSED ACQUISITION OF 806,450 COMMON SHARES IN PANGEN BIOTECH INC. ("PANGEN") ("PANGEN SHARES") REPRESENTING APPROXIMATELY 8.39% EQUITY INTEREST IN PANGEN FROM CHEMICAL COMPANY OF MALAYSIA BERHAD ("CCMB") FOR A TOTAL PURCHASE CONSIDERATION OF RM59.16 MILLION (EQUIVALENT TO KRW16.35 BILLION) TO BE SATISFIED ENTIRELY IN CASH ("PROPOSED ACQUISITION") | The terms used herein, unless the context otherwise stated, bear the same meaning as those defined in the earlier announcements in relation to the Proposed Acquisition.
We refer to the announcements made on 13 April 2018, 16 May 2018, 31 May 2018, 13 June 2018 and 21 June 2018 in relation to the Proposed Acquisition.
On behalf of the Board of Directors of CCMD, UOB Kay Hian Securities (M) Sdn Bhd wishes to announce that the Proposed Acquisition has been completed on 29 June 2019 based on the terms of the SSA.
This announcement is dated 29 June 2018. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 12-7-2018 02:10 AM
|
显示全部楼层
Type | Announcement | Subject | NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
OTHER ISSUE OF SECURITIES | Description | CCM DUOPHARMA BIOTECH BERHAD ("CCMD" OR "THE COMPANY") DIVIDEND REINVESTMENT PLAN | The terms used herein, unless the context otherwise stated, bear the same meaning as those defined in the earlier announcements in relation to the DRP.
We refer to our earlier announcements dated 27 February 2018, 30 March 2018, 11 April 2018 and 31 May 2018 in relation to the DRP.
On behalf of the Board of Directors of CCMD, UOBKH wishes to announce that based on the valid dividend reinvestment forms received by Tricor Investor & Issuing House Services Sdn Bhd, being the Share Registrar of the Company for the DRP, CCMD will be issuing 10,978,985 new CCMD Shares pursuant to the DRP ("New Shares"). The New Shares to be issued represent approximately 80.70% of the total number of 13,604,282 New Shares that would have been issued pursuant to the DRP had all the entitled shareholders of CCMD elected to reinvest their respective Electable Portions of their cash dividend in New Shares.
Barring any unforeseen circumstances, the said New Shares pursuant to the DRP are expected to be listed on the Main Market of Bursa Malaysia Securities Berhad on 18 July 2018.
This announcement is dated 11 July 2018. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 17-7-2018 11:45 PM
|
显示全部楼层
| CCM DUOPHARMA BIOTECH BERHAD |
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Others | Details of corporate proposal | Dividend Reinvestment Plan that provides the shareholders of CCMD with an option to elect to reinvest their single tier final dividend of 6 sen per ordinary share in CCMD for the financial year ended 31 December 2017 in new CCMD Shares | No. of shares issued under this corporate proposal | 10,978,985 | Issue price per share ($$) | Malaysian Ringgit (MYR) 1.2300 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 661,881,056 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 347,188,652.000 | Listing Date | 18 Jul 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 21-7-2018 03:01 AM
|
显示全部楼层
Name | PERMODALAN NASIONAL BERHAD | Address | Tingkat 4, Balai PNB, 201-A Jalan Tun Razak, 50400 Kuala Lumpur.
Kuala Lumpur
50400 Wilayah Persekutuan
Malaysia. | Company No. | 038218X | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | ORDINARY SHARES |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 18 Jul 2018 | 6,377,808 | Others | Direct Interest | Name of registered holder | PERMODALAN NASIONAL BERHAD | Address of registered holder | TINGKAT 4, BALAI PNB, 201-A, JALAN TUN RAZAK, 50400 KUALA LUMPUR. | Description of "Others" Type of Transaction | DRP |
Circumstances by reason of which change has occurred | Elected to reinvest in 6,377,808 new shares pursuant to the Dividend Reinvestment Plan ("DRP"). | Nature of interest | Direct Interest | Direct (units) | 311,449,628 | Direct (%) | 47.055 | Indirect/deemed interest (units) |
| | Indirect/deemed interest (%) |
| | Total no of securities after change | 311,449,628 | Date of notice | 18 Jul 2018 | Date notice received by Listed Issuer | 20 Jul 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 28-8-2018 06:37 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2018 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Jun 2018 | 30 Jun 2017 | 30 Jun 2018 | 30 Jun 2017 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 123,991 | 117,049 | 257,250 | 240,355 | | 2 | Profit/(loss) before tax | 12,915 | 12,642 | 26,170 | 24,764 | | 3 | Profit/(loss) for the period | 10,339 | 9,641 | 20,986 | 19,205 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 10,339 | 9,653 | 20,986 | 19,217 | | 5 | Basic earnings/(loss) per share (Subunit) | 3.69 | 3.46 | 7.50 | 6.88 | | 6 | Proposed/Declared dividend per share (Subunit) | 1.50 | 2.50 | 1.50 | 2.50 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.7300 | 0.7200
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 28-8-2018 06:46 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 9-9-2018 07:19 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 8-10-2018 04:44 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 23-10-2018 05:20 AM
|
显示全部楼层
| CCM DUOPHARMA BIOTECH BERHAD |
EX-date | 02 Nov 2018 | Entitlement date | 07 Nov 2018 | Entitlement time | 05:00 PM | Entitlement subject | First Interim Dividend | Entitlement description | First Interim Single-Tier Dividend of 1.5 sen per ordinary share | Period of interest payment | to | Financial Year End | 31 Dec 2018 | Share transfer book & register of members will be | to closed from (both dates inclusive) for the purpose of determining the entitlement | Registrar or Service Provider name, address, telephone no | TRICOR INVESTOR & ISSUING HOUSE SERVICES SDN BHDUnit 32-01, Level 32, Tower A,Vertical Business Suite, Avenue 3, Bangsar South,No. 8, Jalan Kerinchi59200Kuala LumpurTel:0327839299Fax:0327839222 | Payment date | 23 Nov 2018 | a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers | 07 Nov 2018 | b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit |
| | c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange. | Number of new shares/securities issued (units) (If applicable) |
| | Entitlement indicator | Currency | Currency | Malaysian Ringgit (MYR) | Entitlement in Currency | 0.015 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 27-10-2018 04:59 AM
|
显示全部楼层
本帖最后由 icy97 于 31-10-2018 04:44 AM 编辑
Type | Announcement | Subject | OTHERS | Description | CCM DUOPHARMA BIOTECH BERHAD (CCMD OR COMPANY)- ACQUISITION OF 5.8% EQUITY STAKE IN SCM LIFESCIENCE CO., LTD. | The Board of Directors of CCMD (“Board”) wishes to announce that the Company had on 25 October 2018 entered into the following agreements:- (a) A Share Subscription Agreement (“SSA”) with SCM Lifescience Co., Ltd. (“SCM Lifescience”), Sun U. Song and Byung Geon Rhee (hereinafter Sun U. Song and Byung Geon Rhee are collectively referred to as the “Interested Persons”) for the subscription of164,016 common shares and 109,344 redeemable convertible preference shares (“Purchased RCPS”) representing approximately 5.8% equity stake in SCM Lifescience for a total purchase consideration of Korean Won (“KRW”) 5,500,003,200 (approximately Ringgit Malaysia (“MYR”) 20.24 million) upon the terms and conditions contained in the SSA; and
(b) An Exclusive Marketing and Commercialization Agreement (“EMCA”) with SCM Lifescience on 25 October 2018 in conjunction with the SSA
Further details as per attachment.
This announcement is dated 25 October 2018. |
http://www.bursamalaysia.com/market/listed-companies/company-announcements/5952957
|
|
|
|
|
|
|
|
|
|
|
|
发表于 27-10-2018 05:00 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 5-12-2018 02:59 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | CCM DUOPHARMA BIOTECH BERHAD (CCMD OR COMPANY) - ACQUISITION OF 5.8% EQUITY STAKE IN SCM LIFESCIENCE CO., LTD. | Reference is made to our earlier announcement dated 25 October 2018 ("Announcement"). All abbreviations and definitions used herein shall have the same meaning as the words and expressions defined in the Announcement.
We wish to advise that all applicable conditions precedent as stipulated in the SSA have been fulfilled and the Acquisition has been completed on 23 November 2018.
This announcement is dated 23 November 2018. |
|
|
|
|
|
|
|
|
|
|
| |
本周最热论坛帖子
|
1714 
36
